key: cord-0954306-sj7btahy
authors: Kadri, Sameer S; Demirkale, Cumhur Y; Sun, Junfeng; Busch, Lindsay M; Strich, Jeffrey R; Rosenthal, Ning; Warner, Sarah
title: Real-world Inpatient Use of Medications Repurposed for COVID-19 in U.S. Hospitals, March-May 2020
date: 2020-12-15
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa616
sha: 9c04bd5345d31b3cf3ec0a009f26b93eae66fbaa
doc_id: 954306
cord_uid: sj7btahy

We report off-label use patterns for medications repurposed for COVID-19 at 318 U.S. hospitals. Inpatient hydroxychloroquine use declined by 80%, while corticosteroids and tocilizumab were initiated two days earlier in May versus March 2020. Two-thirds of ventilated COVID-19 patients were already receiving corticosteroids during March-May, resembling pre-COVID use in mechanically ventilated influenza patients.

M a n u s c r i p t

Early in the COVID-19 pandemic, medications approved for other diseases were expeditiously repurposed as candidate therapies against SARS-CoV-2. Clinicians across the world proposed treating patients with numerous different medications. However, the absence of robust evidence supporting these interventions prompted guidance limiting their use to randomized clinical trials (RCTs).

Hydroxychloroquine and azithromycin were entered into large RCTs based on suppression of SARS-CoV-2 replication, whereas corticosteroids and the interleukin-6 receptor antagonist tocilizumab were similarly studied due to their potential for mitigating immune-mediate organ injury.(1, 2) Nonetheless, the frequency and significant morbidity of COVID-19 may have prompted clinicians to continue using these agents as usual care outside of RCTs. Contemporaneous changes in evidence, regulatory policy and drug supplies may have also impacted the extent and timing of prescribing in hospitals. We aimed to characterize whether, how and why utilization changed in U.S. hospitals for key systemically administered, repurposed agents with putative anti-SARS-CoV-2 (hydroxychloroquine, azithromycin), and immunosuppressive (corticosteroids and tocilizumab) effects.

The Premier Healthcare database (PHD), a large, all-payer administrative repository that covers approximately 20% of U.S. hospitalizations across 48 States, was queried for initial inpatient encounters of adults (≥18 years) with diagnosis coding indicative of COVID-19 admitted to continuously-reporting hospitals between March 1 st -May 31 st , 2020. Patients discharged prior to availability of the COVID-19-specific diagnosis code (U07.1), were identified based on CDC guidance A c c e p t e d M a n u s c r i p t (i.e. coding for an acute lower respiratory tract illness along with other coronavirus as the cause of diseases classified elsewhere (B97.29); eTable1).(3) Each agent's usage was examined at the hospital and patient level and calculated as the proportion of encounters recording ≥ 1 administration. The day of drug initiation relative to hospital admission and intubation day respectively were compared for each drug by month. Encounters with an ICD-10 diagnosis code for influenza (J09.x, J10.x, J11.x) during the last peak influenza season between December-February 2020 were examined as a reference standard to gauge pre-COVID-19 usage.

We performed multivariable logistic regression modeling to estimate the association between select covariates and the primary outcome of monthly medication usage. Generalized estimating equations accounted for within-hospital clustering and correlation. Variables were pre-specified for inclusion in the multivariable model based on clinical knowledge of potential confounding over time, biologic plausibility, and completeness of data. The model was risk-adjusted for age, sex, race/ethnicity, insurance and transfer status, Elixhauser Comorbidity Index, length-of-stay, traditional prescribing indications (eTable2) as well as acute organ failures present-on-admission. Acute organ failures were identified by cross walking the ICD-9 adaptation of the Acute Organ Failure Score to ICD-10 using an online tool.(4) Risk-adjusted monthly usage rates for each of the four medications were analyzed separately for non-ventilated and mechanically ventilated cohorts.

A sensitivity analysis was conducted limited to medication initiations within 10 days of admission (see additional methods in supplement). Reporting of relevant study results, guidelines and regulatory policy changes were superimposed on monthly trends (eTable3). Results were visually compared for clinically-meaningful differences and tests for statistical significance were not applied Overall, the use of hydroxychloroquine and azithromycin was higher for mechanically ventilated vs. non-ventilated patients respectively but the relative difference was much greater for corticosteroids and tocilizumab. Compared to non-ventilated COVID-19 patients, mechanically ventilated COVID-19 patients were 3-fold more likely to receive corticosteroids (22.0 vs. 61.8%) and 6-fold more likely to received tocilizumab (3.0 vs 18.9%). The use of corticosteroids among mechanically ventilated COVID-19 patients (at 62%) was comparable to its use among pre-COVID-19, mechanically ventilated influenza patients (at 68%; eFigure 3A-B).

Over the 3-month period, hydroxychloroquine use rate decreased by 81% and 79%, while azithromycin use rate decreased by 46% and 51% among non-ventilated and mechanically ventilated encounters respectively (Figure 1 ). On the other hand, corticosteroid use rate for A c c e p t e d M a n u s c r i p t increased among both mechanically ventilated and non-ventilated patients, whereas tocilizumab use rate remained relatively stable, especially among mechanically ventilated patients. Most were initiated within the first 10 days of admission; the 10-day restriction for medication initiation in the sensitivity analysis resulted in excluding 112 (0.7%) hydroxychloroquine, 41 (0.2%) azithromycin, 628 (6.2%) corticosteroids and 140 (6.9%) tocilizumab encounters and generated trends that were similar to those from the primary analysis (eTable6).

March respectively (Figure 2 ). Among mechanically ventilated patients, median initiation of hydroxychloroquine and azithromycin continued to occur on or prior to the intubation day over the study period. On the other hand, the median day of initiation for corticosteroids and tocilizumab among mechanically ventilated patients occurred on the day of intubation in May compared to oneand two-days post-intubation in March, respectively. Notably, the median day to intubation remained the second hospital day across all three study months.

Our study offers important population-level insights into how, when and possibly why inpatient Our study has limitations. Despite its large and all-payer nature, PHD is a convenience sample of U.S. hospitals and may not have been nationally representative. However, the national COVID-19 landscape remains dynamic. Fewer May (versus March/April) admissions may have received discharge dispositions when hospitals submitted data. Date jumbling in the commercially-leased version of PHD precludes temporal granularity beyond the month-level. However, our sensitivity analysis mitigates concern for admission month misrepresenting the month of medication initiation.

We did not focus on unapproved agents as they often evade administrative data due to investigational usage or incomplete mapping early on. The uptake and accuracy of recently A c c e p t e d M a n u s c r i p t introduced procedure codes representing the use of remdesivir, convalescent plasma and other newer agents will need to be closely tracked in order to determine whether they are reliable for pharmacoepidemiologic proposes. (19) Our study suggests that in times necessitating desperate measures, usual care may be greatly influenced by suboptimal evidence, mass media, experiences from analogous and anecdotal clinical scenarios coupled with need to "do something", especially for severely ill patients. Future candidate agents may not necessarily be met with the serendipitous success achieved with pre-evidence-based adoption of corticosteroids or the early warnings signals of harm that were available for hydroxychloroquine. Variable uptake across hospitals in the use of these repurposed agents for COVID-19 is testament to the lack of a perceived standard-of-care early on. Moving forward, the provider, guideline and regulatory communities may need to carefully and prospectively weigh the urge for earlier real-world adoption of new and repurposed agents against not only potential direct harms, but also the risk of delaying systematic generation of more definitive evidence. M a n u s c r i p t 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

ICD-10-CM Official Coding Guidelines -Supplement Coding encounters related to COVID-19 Coronavirus Outbreak

Adaptation of the Acute Organ Failure Score for Use in a Medicare Population

Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis

Emergency Use Authorization For Use of Chloroquine Phosphate or

Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Co-infections in people with COVID-19: a systematic review and meta-analysis

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19

Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Emergency Use Authorization of convalescent plasma for treatment of hospitalized patients with COVID-19

Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience

A c c e p t e d M a n u s c r i p t